This review discusses the limitations of conventional animal models and two-dimensional cultures in studying cutaneous pigmentary disorders such as vitiligo, melasma, post-inflammatory hyperpigmentation, and solar/senile lentigines. It evaluates advanced in vitro models, including exvivoexplants, co-cultures, three-dimensional skin equivalents, bioprinted constructs, organoids, and skin-on-a-chip platforms. These models are assessed based on their ability to replicate human pigmentation processes, disease-specific pathological processes, and their potential for mechanistic studies and therapeutic evaluation. The review highlights challenges such as vascular and immune integration, long-term stability, and regulatory acceptance, emphasizing the need for improved models within the framework of New Approach Methodologies.
ABS-201 shows promise for male hair regrowth by blocking the prolactin receptor, with higher expected efficacy than current treatments. The discussion also covers dosing differences between macaques and humans for hmi115, highlighting a significant dosage disparity.
The conversation discusses hair loss treatments, specifically Brassica oleracea extract, glucosinolates, and sulforaphane, and their potential to promote hair growth. Users also mention minoxidil and finasteride as existing treatments.